Browse Antineoplastic agents topic

Licensing agreements subtopic

Articles 1-14 out of 14 article(s) Title Author Type Date Words GPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for Satraplatin. Aug 6, 2008 392 BioInvent and ThromboGenics Announce a Strategic Alliance with Roche for TB-403, A Novel Anti-Cancer Antibody. Jun 18, 2008 1395 Morphotek(R) Signs Exclusive Licensing Agreement for Anti-Cancer Antibody. Mar 6, 2008 492 Caprion Pharmaceuticals Enters Into Oncology Target Licensing Agreement with Centocor Research and Development, Inc. Oct 11, 2006 269 MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection; Ex-North America Development & Commercialization Agreement. Jul 6, 2006 919 Florida Atlantic licenses cancer therapy to CHS Resources LLC Therapy. Jun 1, 2006 1346 Affitech Renews Exclusive Worldwide Phage Display License From DKFZ; 'Breitling' Patents Hold Key Position in Human Antibody Discovery Field. Apr 9, 2006 332 Immusol Announces an Exclusive Worldwide License Agreement with Baylor College of Medicine for a Novel Cancer Therapy. Feb 1, 2006 514 Caprion Pharmaceuticals Enters Into Oncology Target Licensing Agreement with ImClone Systems. Jan 10, 2006 319 Sonus Pharmaceuticals and Schering AG Announce Global Licensing Agreement for Anti-cancer Product TOCOSOL(R) Paclitaxel. Oct 18, 2005 1352 EntreMed and Celgene enter into licensing agreement for the development of tubulin inhibitor cancer drugs. Mar 1, 2005 575 Prolexys licenses anti-cancer compounds. Feb 1, 2005 435 Protein Design Labs licenses development rights to leukemia antibody. Mar 1, 2003 530 FDA approves Novartis' Gleevec for first line treatment of chronic myeloid leukemia. Brief Article Dec 27, 2002 171